InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
null
InspireMD, Inc. Q1 2026 Earnings Call Summary
null
InspireMD (NSPR) Q2 2025 Earnings Transcript
null
InspireMD (NSPR) Q4 2025 Earnings Transcript
null
InspireMD Reports First Quarter 2026 Financial Results
null
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
null
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
null
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
null
InspireMD to Announce First Quarter 2026 Financial Results
null
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR)
null
InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
null
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results
null
InspireMD Inc (NSPR) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Advancements
null
InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates
null
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
null
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates
undefined
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Management Changes
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
#Product Stage
InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago
undefined
Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth?
undefined
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting
#Product Stage
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference
undefined
InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates
undefined
InspireMD Reports Third Quarter 2025 Financial Results
#Product Stage #Management Changes #Investment
InspireMD Inc (NSPR) Q3 2025 Earnings Call Highlights: Robust Revenue Growth Amid Rising Expenses
#Product Stage #Customers #PIPE #Expand
InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer
#Management Changes
Hologic (HOLX) Q4 Earnings and Revenues Beat Estimates
undefined
Pleasing Signs As A Number Of Insiders Buy InspireMD Stock
undefined
InspireMD to Announce Third Quarter 2025 Financial Results
undefined
Intuitive Surgical, Inc. (ISRG) Q3 Earnings and Revenues Top Estimates
undefined
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
Parkman Healthcare Expands Stake in InspireMD Backing Carotid Innovation
#Investment #Management Changes #Expand
InspireMD Announces the Appointment of Dan Dearen to its Board of Directors
#Management Changes
InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference
undefined
InspireMD Reports Second Quarter 2025 Financial Results
null
RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
#Management Changes
Investors in InspireMD (NASDAQ:NSPR) from five years ago are still down 60%, even after 11% gain this past week
undefined
InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors
#Management Changes
InspireMD Announces Combined Financings of $58 Million
#Investment #PIPE #FDA approved
InspireMD to Announce Second Quarter 2025 Financial Results
undefined
CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?
undefined
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
#Product Stage #FDA approved/pending approval
InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke
#Product Stage #Customers
InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke
#FDA approved/pending approval
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
#Product Stage
InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer
#Management Changes
InspireMD Inc (NSPR) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges
#Product Stage #Layoffs
InspireMD Reports First Quarter 2025 Financial Results
#Product Stage #Management Changes #Expand
InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference
undefined
InspireMD to Announce First Quarter 2025 Financial Results
undefined
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
undefined
InspireMD Full Year 2024 Earnings: US$0.76 loss per share (vs US$0.82 loss in FY 2023)
undefined
InspireMD Inc (NSPR) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses and ...
#Product Stage #Expand
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results
#Product Stage #FDA approved/pending approval
InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results
undefined
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 78% over the last five years
undefined
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures
#Product Stage #Partners
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Management Changes
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
Here's Why We're Watching InspireMD's (NASDAQ:NSPR) Cash Burn Situation
undefined
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025
#Management Changes
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
undefined
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
#Management Changes
InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)
undefined
InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ...
#Expand
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update
#Expand
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
#Expand
InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th
undefined
One InspireMD Insider Raised Stake By 13% In Previous Year
undefined
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
#Expand
InspireMD Advances with FDA Study Approval and Global Goals
undefined
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
#Customers
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
#Customers
Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 88% over the last five years
undefined
Companies Like InspireMD (NASDAQ:NSPR) Are In A Position To Invest In Growth
#Investment
InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
#Investment
InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment
#Investment
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th
#Investment
InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
#Investment
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024
#Investment #Expand
InspireMD Insider Ups Holding By 13% During Year
#Investment
InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update
#Investment #Management Changes
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th
#Investment
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
#Management Changes
InspireMD's (NASDAQ:NSPR) investors will be pleased with their solid 110% return over the last year
#Public Trading
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
#Investment #Expand
InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript
#Customers #Investment #Expand
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
#Customers #Management Changes #Partners
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
undefined
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
#Management Changes #Expand
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
#Customers
We're Hopeful That InspireMD (NASDAQ:NSPR) Will Use Its Cash Wisely
#Investment
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
#Management Changes
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
#Investment
InspireMD's Gary Roubin Acquires 13% More Stock
#Investment
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
#Partners #Investment
InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript
#Customers #Management Changes
InspireMD Inc (NSPR) Reports Q3 2023 Financial Results: CGuard EPS Revenue Increases by 9% ...
#Customers #Expand
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
#Management Changes
InspireMD to Participate in Upcoming November Investor Conferences
#Investment
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
#Customers
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th
#Investment
InspireMD's (NASDAQ:NSPR) investors will be pleased with their impressive 179% return over the last year
#Investment
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
#Customers #Expand
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
#Management Changes #Expand
Favourable Signals For InspireMD: Numerous Insiders Acquired Stock
#Investment
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
#Partners #Investment
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
#Investment
InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th
#Investment
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
#Customers #Investment
Israeli stent co InspireMD raises up to $113m
#Investment
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
#Management Changes
InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update
#Investment #Management Changes
InspireMD Announces Private Placement of Up to $113.6 Million
#Investment
InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast
#Public Trading
InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update
undefined
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
#Customers #Investment
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
undefined
InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update
#Investment #Management Changes
InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
undefined
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer
undefined
InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update
undefined
InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing
undefined
InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing
#Management Changes
InspireMD Announces “12 Days of Carotid Stenting” Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists
#Customers
InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium
undefined
InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update
undefined
InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update
undefined
InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference
undefined
NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development
undefined
InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update
undefined
InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update
undefined
InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor
undefined
InspireMD Announces Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2020
#Customers
InspireMD's CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany
#Partners #Customers
InspireMD Announces Publication of Meta-Analysis Citing Benefits of Next Generation Mesh-Covered Carotid Stent Systems
#Customers
InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
#Customers
InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia
#Customers
InspireMD Announces Regulatory Approval of CGuard Embolic Prevention System in Mexico
#Customers
https://markets.businessinsider.com/news/stocks/inspiremd-announces-issuance-of-two-new-u-s-patents-covering-proprietary-micronet-stent-jacket-and-related-drug-eluting-technology-1027539364
#Customers #Partners
InspireMD Receives Regulatory Approval for both CGuard™ EPS and MGuard Prime™ in Ecuador - InspireMD
#Partners
http://www.marketwired.com/press-release/inspiremd-announces-planned-recapitalization-2242135.htm
#Investment
InspireMD closes $15m offering
#Investment